Lightnews — Scholar-powered news

EMJ GOLD @emjgold.bsky.social · 19h

🧠 New partnership in brain health

Lundbeck is stepping into RNA-targeted drug discovery via a collaboration with Contera Pharma, with hopes to identify new oligonucleotide-based therapies.

Read now: emjreviews.com/emj-gold/news/lundbeck-and-contera-partner-on-rna-targeted-drug-discovery/

Lundbeck and Contera partner on RNA-targeted drug discovery

Lundbeck is partnering with Contera Pharma to accelerate RNA-targeted drug discovery for serious neurological conditions.

emjreviews.com

EMJ GOLD @emjgold.bsky.social · 8d

AstraZeneca’s landmark deal with the White House promises up to 80% off drug prices, but what has the US government offered in return?

Find out here: www.emjreviews.com/emj-gold/new...

AstraZeneca to offer up to 80% off US drug prices

AstraZeneca joins Trump’s drug pricing plan, pledging $50bn US investment and discounts of up to 80% to cut prescription medicine costs.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · 9d

The NIHR has announced over £1.5m in funding for 17 innovative health tech projects across the UK.

Discover the recipients: www.emjreviews.com/emj-gold/new...

NIHR funds £1.5m in innovative digital health projects

The UK's NIHR has funded £1.5M for 17 digital health projects to reduce paediatric mental health waiting times.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · 12d

"It’s not just about removing inflammation, but for people to accept, like and feel comfortable in their skin again"

This #WorldMentalHealthDay, Dr Volker Koscielny, Almirall, explores the need to better address the mental health burden of skin conditions hubs.ly/Q03N3VZB0

1

EMJ GOLD @emjgold.bsky.social · 13d

A new biotech company believes the brain could hold the key to treating immune diseases.

Headed up by CEO Dr Kim Seth, #NiloTherapeutics have earned $101m in funding to explore their hypothesis.

Discover more: www.emjreviews.com/emj-gold/new...

Could the brain be a target for autoimmune disease?

A new biotech company Nilo Therapeutics believes the brain could hold the key to treating autoimmune diseases, with further studies to follow.

www.emjreviews.com

EMJ GOLD @emjgold.bsky.social · 14d

Is £30,000 still the right price for a year of good health?

NICE's cost-effectiveness threshold hasn’t changed since 1999, and the @abpi.bsky.social says it’s time for a rethink.

Read the story: www.emjreviews.com/emj-gold/new...

ABPI calls for NICE cost-effectiveness threshold review

ABPI is urging NICE to raise its cost-effectiveness threshold for new medicines, which has not been raised in over 20 years.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · 18d

🧠 What if mind-controlled devices didn’t require invasive surgery?

A new study by Precision Neuroscience shows a surface-based brain-computer interface can capture high-resolution signals without opening the skull.

Read more: www.emjreviews.com/emj-gold/new...

Potential breakthrough in brain-computer interface research

New research from Precision Neuroscience shows its brain-computer interface can record high-resolution signals without invasive surgery.

www.emjreviews.com

2

EMJ GOLD @emjgold.bsky.social · 19d

UK healthcare stocks are powering the FTSE 100 to record highs - with AstraZeneca leading the charge and policy shifts in the US opening new doors for pharma. Could this be the turning point for the sector?

Read the full story here: www.emjreviews.com/emj-gold/new...

FTSE 100 hits new high as UK pharma stocks surge

UK pharma and healthcare stocks drive FTSE 100 to a record high, led by AstraZeneca, as trade policy shifts boost investor confidence.

www.emjreviews.com

EMJ GOLD @emjgold.bsky.social · 20d

Pharma headlines only tell part of the story.

Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.

Read now: www.emjreviews.com/emj-gold/new...

EMJ GOLD @emjgold.bsky.social · 21d

🚨 England’s first fully digital hospital is coming

Hear from NHS leaders and patient groups on what NHS Online could mean for the future of healthcare in England.

Read more: www.emjreviews.com/emj-gold/new...

NHS Online digital hospital to launch by 2027

England’s NHS is launching NHS Online, a fully digital hospital, to speed up specialist appointments, cut wait times and improve care access.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · 26d

What could the tariffs mean for your company?

Announcing the plan on his Truth Social platform, President Trump said drugmakers could avoid the 100% duties if they have broken ground on a domestic plant on US soil.

Learn more: www.emjreviews.com/emj-gold/new...

#pharmatariffs

US pharma tariffs: Trump threatens 100% on imports

Donald Trump has threatened sweeping new tariffs on the pharma sector unless manufacturers commit to producing in the US.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · 27d

Social media: What does pharma need to know in 2025?

Discover key trends, challenges and opportunities, with some surprises in store, in our latest article.

Check it out now: www.emjreviews.com/emj-gold/art...

4

EMJ GOLD @emjgold.bsky.social · 29d

Can Pfizer become an obesity market leader?

With its $4.9bn acquisition of Metsera, the pharma giant is signalling its desire to conquer one of the industry’s fastest-growing areas.

Read the story: www.emjreviews.com/emj-gold/new...

Pfizer enters obesity race with $4.9bn Metsera deal

Pfizer is claiming a space in the global obesity market as it announces plans to acquire weight loss drug developer Metsera for $4.9bn.

www.emjreviews.com

2

EMJ GOLD @emjgold.bsky.social · Sep 18

Roche is set to acquire US-based 89bio in a deal worth up to $3.5B.

The acquisition brings a late-stage therapy for MASH - an area with no approved treatments - into Roche’s pipeline, strengthening its focus on cardiovascular, renal and metabolic diseases: www.emjreviews.com/emj-gold/new...

Roche acquires US biotech 89bio for $3.5bn

Roche acquires 89bio in a $3.5B deal, adding a late-stage MASH therapy and expanding its focus on cardiovascular and metabolic diseases.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · Sep 18

Can ChatGPT really be trusted for medical advice?

A new study suggests not yet. When researchers tested the AI on common patient questions about COPD, they found its answers were consistent, but often incomplete.

Read more: www.emjreviews.com/emj-gold/new...

New study reveals risks of patients using ChatGPT

Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.

www.emjreviews.com

1 1

EMJ GOLD @emjgold.bsky.social · Sep 17

Germany was once the “pharmacy of the world”.

Today, its strengths in research, investment and patient access give it a chance to reclaim that crown. But with hurdles in financing, regulation and digital adoption, the question is: can it lead the pack once more?
www.emjreviews.com/emj-gold/art...

EMJ GOLD @emjgold.bsky.social · Sep 16

The UK is slipping in the global pharma race. An ABPI & PwC report shows R&D growth, investment, and clinical trial activity are all in decline. Urgent action is needed to stay competitive.

Read more 👉 www.emjreviews.com/emj-gold/new...

ABPI report highlights decline in UK pharma investment

UK falls in global pharma R&D and clinical trials competitiveness, ABPI report warns, urging action to unlock investment and patient access.

www.emjreviews.com

EMJ GOLD @emjgold.bsky.social · Sep 16

Could one therapy treat 100+ diseases?

According to Phesi, GLP-1s, once for diabetes and weight loss, are now in trials across cancers, MASLD, PCOS and more. But what challenges lie ahead?

Discover now: www.emjreviews.com/emj-gold/new...

GLP-1 therapies in trials for 100+ diseases, Phesi finds

Phesi analysis shows GLP-1 therapies moving beyond diabetes and obesity into 100+ diseases, from cancer to cardiovascular conditions.

www.emjreviews.com

EMJ GOLD @emjgold.bsky.social · Sep 10

🚨 Novo Nordisk to cut 9,000 jobs as part of a major restructuring.

Savings will be reinvested in growth opportunities in #diabetes and #obesity treatments.

Read the story: www.emjreviews.com/emj-gold/new...

Novo Nordisk cuts jobs to fund diabetes and obesity growth

Novo Nordisk announces 9,000 job cuts to streamline operations and reinvest in diabetes and obesity growth, aiming for long-term efficiency.

www.emjreviews.com

1

EMJ GOLD @emjgold.bsky.social · Sep 10

"Great leadership is about navigating paradoxes. You’ve got to think big and long-term, while delivering flawlessly day to day."

In our latest interview, hear from Fabrice Chouraqui, CEO, Pharming, as he shares his top leadership lessons and more.

🔗 www.emjreviews.com/emj-gold/art...

5 minutes with Fabrice Chouraqui, CEO, Pharming

Fabrice Chouraqu, CEO, Pharming, explores his journey into the pharma industry, a typical day for a CEO and his key leadership lessons.

hubs.la

1

EMJ GOLD @emjgold.bsky.social · Sep 10

Can smaller biotechs finally compete on drug discovery?

Eli Lilly and Company’s TuneLab will share AI models to support new innovation, joining a wave of other pharma companies opening up their platforms.

Read the story: hubs.ly/Q03HzMxl0

Lilly's TuneLab to share AI models with small biotechs

Lilly has launched TuneLab, giving biotech companies access to AI-powered drug discovery models based on over £1bn in research investment.

hubs.ly

1

EMJ GOLD @emjgold.bsky.social · Sep 3

Celebrating the future of science! 🌟

Thermo Fisher Scientific has recognised 300 of America’s brightest middle school innovators in the 2025 Junior Innovators Challenges, tackling real-world challenges from AI to disease detection and sustainability.

Read more: www.emjreviews.com/emj-gold/new...

Rising STEM stars take home Thermo Fisher Award

A group of 300 middle schoolers are named in the 2025 Thermo Fisher Junior Innovators Challenge for STEM projects in AI to climate change.

hubs.la

1

EMJ GOLD @emjgold.bsky.social · Sep 3

🚨 Big investment in UK health tech

Newcastle University has secured £22m from NIHR to expand its horizon scanning work – with the aim of identifying the next medicines, diagnostics and digital tools set to transform care.

Read more: www.emjreviews.com/emj-gold/new...

Newcastle University wins £22m UK's NIHR health tech award

The National Institute for Health and Care Research (NIHR) is funding Newcastle Univeristy's work in emerging diagnostics, devices and more.

hubs.la

1

EMJ GOLD @emjgold.bsky.social · Aug 26

Pharma is taking psychedelics seriously. AbbVie has just made a billion-dollar bet on a next-generation therapy for depression. See why they invested in this candidate from Gilgamesh Pharmaceuticals👉 www.emjreviews.com/emj-gold/new...

1

EMJ GOLD @emjgold.bsky.social · Aug 21

A new roundtable is live – and this one’s for the pharma marketers.

We spoke to leaders from across the industry to uncover what’s cutting it with today’s HCPs. Unsurprisingly, there are shared challenges, but also plenty of potential solutions.

Read now: hubs.la/Q03DNkV40

1